DALLAS, May 03, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Puration, Inc. (USOTC: PURA (“PURA”) and Kali-Extracts (Kali, Inc. aka Kali-Extracts) (USOTC: KALY) (“KALY”) today issued a joint communication to shareholders regarding the news about Mondelez International adding CBD to some of its products. News out yesterday reported that Mondelez International, the maker of Chips Ahoy, Oreo, Cadbury chocolate, Nilla Wafers and Nutter Butter cookies, is considering adding CBD to some of its products.
“Yes, we’re getting ready, but we obviously want to stay within what is legal and play it the right way,” Van de Put [Mondelez CEO Dirk Van de Put] told CNBC.
PURA has the only license of U.S. Patented Cannabis Extraction process owned by KALY. PURA now has two years of experience producing and refining a CBD infused beverage, EVERx CBD Sports Water. PURA has worked closely with KALY to refine its EVERx CBD Sports Water into the leading CBD infused beverage in the sports nutrition market in addition to developing new CBD infused beverages to be introduced soon. PURA reported over $1 million in sales in 2018. With PURA contributing production experience and capacity, KALY has introduced its own CBD infused confections under the brand name Hemp4mula starting first with Hemp4Mula gum. PURA’s EVERx CBD Sports Water and KALY’s Hemp4mula gum are available for sale today online at www.USMJ.com. The USMJ Ecommerce site comes from North American Cannabis Holdings, Inc. (aka USMJ) (USOTC: USMJ) (“USMJ”).
PURA and KALY continue to work closely together on their years long strategy to introduce leading CBD infused products to market. Management of the two companies see the Mondelez news as a validation of PURA and KALY’s business strategies and progress. Management of the two companies anticipate that developments such as the recent news from Mondelez will bode well for PURA and KALY in the form of garnering new investment to fuel business expansion and in regard to growing consumer demand for CBD infused products.
To learn more about the two companies visit:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.